(EVT) Evotec SE - Ratings and Ratios

Evotec SE is a leading global drug discovery and development partner, offering comprehensive services to the pharmaceutical and biotechnology industries. The company operates through two primary business segments: Shared R&D and Just - Evotec Biologics. Its focus spans a broad range of therapeutic areas, including oncology, autoimmune diseases, diabetes, heart failure, fibrosis, immunology, pain and inflammation, infectious diseases, kidney and liver disorders, rare diseases, respiratory conditions, CNS and cardio-metabolic disorders, as well as animal and womens health. Evotec SE leverages its expertise in innovation-driven drug discovery to address unmet medical needs across these areas.

The company has established a robust network of collaboration agreements with prominent academic institutions, research centers, and industry leaders. Key partnerships include Mass General Brigham and Joslin Diabetes Center for cardiometabolic diseases, BMS for antiviral therapies, Novo Nordisk for cell therapy, and the University of Oxford, among others. Evotec SE also collaborates with venture capital firms and patient advocacy groups to accelerate the development of innovative treatments. Additionally, it maintains strategic partnerships with Bayer, Novo Nordisk, Eli Lilly, and Novartis for kidney disease research, and with Sandoz for biosimilar development.

Evotec SE, formerly known as Evotec AG, was founded in 1993 and rebranded as a Societas Europaea (SE) in April 2019. Headquartered in Hamburg, Germany, the company has grown into a global player in the pharmaceutical industry, with a strong emphasis on innovation and collaboration. Its financial profile reflects a market capitalization of 1,303.95M EUR, with a forward P/E ratio of 61.35, indicating high growth expectations. The companys price-to-book ratio stands at 1.35, and its price-to-sales ratio is 1.64, signaling moderate valuation relative to its revenue.

Based on the provided data, the 3-month forecast for Evotec SE suggests continued upward momentum. The last price of 7.62 EUR exceeds the SMA 20 (6.35) and SMA 50 (6.74), indicating short-term bullish sentiment. The SMA 200 (7.33) may act as resistance. With an ATR of 0.37, volatility is expected to remain low. Fundamentally, the forward P/E of 61.35 reflects strong growth expectations, while the P/S ratio of 1.64 aligns with industry standards. Overall, the stock is likely to maintain its positive trajectory, supported by its robust pipeline and strategic collaborations.